Phone
(504) 584-6990
Fax
(504) 584-6980
feedback@marybird.com
Carrie Marquette, M.D.
- GenitoUrinary Medical Oncology
Mary Bird Provider
Dr. Carrie Marquette is a medical oncologist at Mary Bird Perkins Cancer Center in Metairie, and is part of the GU Oncology team with a focused specialization on the multidisciplinary treatment of patients with GU Cancers (Prostate, Bladder, Kidney, and Testis). She earned her undergraduate degree from the University of Wisconsin in Madison and went on to complete her medical degree at the University of Wisconsin School of Medicine and Public Health.
Dr. Marquette pursued her residency in Internal Medicine at the University of Alabama at Birmingham, where she also completed her fellowship in Hematology and Oncology.
At Mary Bird Perkins Cancer Center, Dr. Marquette is committed to providing patient-centered care, working alongside a team of experts to deliver comprehensive cancer treatments and the latest therapies available to her patients.
Affiliations
Mary Bird Perkins Cancer Center
Experience & Training
Residency: Categorical Internal Medicine; University of Alabama; Birmingham, AL
Fellowship: Hematology and Oncology; University of Alabama; Birmingham, AL
Education
Undergraduate: University of Wisconsin; Madison, WI
Medical: University of Wisconsin School of Medicine and Public Health; Madison, WI
Certifications
Publications
Marquette C, Grant S, DeShazo M, Reddy V, Cantor A, Miley D, Jerome M, Robert F. Phase II study of metronomic chemotherapy with bevacizumab in patients with advanced non-squamous non-small cell lung cancer. Abstract 8057. ASCO 2013.
Marquette CL, Johnson LE, McNeel DG. Medical Student Fall Research Forum, Madison, WI. Prostatic acid phosphatase DNA vaccine biodistribution study. 10/2004.
Johnson LE, Frye TP, Arnot AR, Marquette CL, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase. Vaccine 2005; 24: 293-303.
Marquette C, Nabell L. Chemotherapy-Resistant Metastatic Breast Cancer. Current Treatment Options in Oncology. 2012; 13: 263-75.
Related Press Releases